Credit Suisse Upgrades Johnson & Johnson to Buy

By Carrie Williams

In a report issued on April 12, Vamil Divan from Credit Suisse upgraded Johnson & Johnson (NYSE: JNJ) to Buy, with a price target of $154. The company’s shares closed yesterday at $130.62.

According to, Divan is ranked 0 out of 5 stars with an average return of -3.3% and a 40.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Eli Lilly & Co.

Currently, the analyst consensus on Johnson & Johnson is Moderate Buy and the average price target is $144.67, representing a 10.8% upside.

In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $153 price target.

Based on Johnson & Johnson’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $20.19 billion and GAAP net loss of $10.71 billion. In comparison, last year the company earned revenue of $17.8 billion and had a net profit of $4.42 billion.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. Most recently, in February 2018, Paulus Stoffels, the Exec VP, Chief Scientific Off of JNJ sold 155,342 shares for a total of $20,171,159.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.